Compare ARK Genomic Revolution ETF (ARKG) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Schwab US Dividend Equity ETF — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Schwab US Dividend Equity ETF trades at $32.49. Which is the better fit depends on your goals.
| ARKG | SCHD | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $43.57 | $32.83 |
52-Week Low | $23.09 | $26.38 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
SCHD trades at $32.40, up 0.43% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on U.S. dividend equities, offering a yield around 3.2%, and has shown strong performance in 2026, outpacing the S&P 500. Recent news highlights its appeal for long-term income investors, though some analysts note underperformance concerns versus broader indices.
Outlook remains positive for dividend-focused portfolios, supported by quality stock selection and low fees. Key risks include interest rate sensitivity and market rotation away from value stocks. Institutional sentiment is mixed, with bullish technicals contrasting with fundamental debates on total returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
